Eliquis Denied by Insurance? How to Appeal

Eliquis (apixaban, NDC: 00003-0894-11 for 5 mg; 00003-0893-11 for 2.5 mg) is one of the most widely prescribed anticoagulants in the world — and one of the most frequently denied by insurance due to its cost ($400–$600/month without assistance). Insurers routinely require step therapy to warfarin, even when clinical evidence clearly supports apixaban's superiority for most patients. Here is how to fight back effectively.

Why Insurers Deny Eliquis

Warfarin step therapy required. The most common denial reason. The insurer requires you to try warfarin (coumadin, a generic costing $10–$30/month) first. However, major clinical trials and AHA/ACC guidelines establish that DOACs are clinically superior to warfarin for most AFib and VTE patients.

Non-preferred formulary status. Some plans cover another DOAC (rivaroxaban/Xarelto, dabigatran/Pradaxa, edoxaban/Savaysa) as preferred and require non-preferred exception justification for Eliquis.

Diagnosis code mismatch. The submitted ICD-10 code does not match the PA criteria (e.g., valvular AFib submitted instead of non-valvular AFib, which is the FDA-approved indication).

Indication not covered. While apixaban has multiple FDA indications, some PA criteria are narrow. Confirm the PA request correctly identifies the indication being treated.

FDA-Approved Indications for Eliquis (Apixaban)

1. Non-valvular atrial fibrillation (AFib): Reduce risk of stroke and systemic embolism (ICD-10: I48.0–I48.19, I48.20–I48.91)
2. DVT treatment: Treatment of acute deep vein thrombosis (ICD-10: I82.x series)
3. PE treatment: Treatment of acute pulmonary embolism (ICD-10: I26.x series)
4. DVT/PE secondary prevention: Reduce risk of recurrent DVT and PE after initial treatment
5. Post-surgical VTE prophylaxis: Prevention after knee or hip replacement surgery (ICD-10: Z96.641, Z96.651)

Clinical Evidence Supporting Eliquis Over Warfarin

The core of your appeal: clinical trial evidence and cardiology guidelines establish Eliquis superiority over warfarin for most patients, making warfarin step therapy clinically inappropriate.

ARISTOTLE Trial (NEJM 2011) — AFib indication:

• 21% relative risk reduction in stroke or systemic embolism vs. warfarin (p<0.001)
• 31% relative risk reduction in major bleeding vs. warfarin (p<0.001)
• 11% reduction in all-cause mortality (p=0.047)
• This is the key trial for any AFib-related Eliquis denial appeal

AMPLIFY Trial (NEJM 2013) — DVT/PE treatment:

• Non-inferior to warfarin for efficacy in DVT/PE treatment
• 69% relative risk reduction in major bleeding vs. warfarin
• Demonstrates Eliquis superiority in safety for VTE treatment

AHA/ACC/HRS 2023 Atrial Fibrillation Guidelines:

• Class I recommendation (Level A evidence): DOACs are recommended over warfarin for patients with non-valvular AFib with CHA₂DS₂-VASc score ≥2 (men) or ≥3 (women)
• This is the strongest possible guideline recommendation and directly contradicts step therapy requirements

Clinical Arguments Against Warfarin Step Therapy

Document why warfarin is clinically inappropriate for your patient using one or more of these arguments:

Labile INR history. Prior warfarin use with time-in-therapeutic range (TTR) <65% demonstrates inadequate INR control and supports DOAC use without further warfarin trial.

Renal considerations. Apixaban is the preferred DOAC in moderate renal impairment (CrCl 15–29 mL/min) due to lower renal clearance (27%) compared to rivaroxaban or dabigatran.

Drug interactions. Warfarin has extensive CYP450-mediated drug interactions. If the patient is on interacting medications (amiodarone, azole antifungals, rifampin, multiple antibiotics), warfarin management is clinically more complex.

Monitoring burden. INR monitoring requires frequent blood testing. Patients with limited mobility, rural access, or work constraints may have legitimate reasons for preferring a DOAC that does not require routine monitoring.

Prior adverse events on warfarin. If the patient had major bleeding, subtherapeutic INR resulting in stroke/TIA, or angioedema on warfarin, document this history explicitly.

CHA₂DS₂-VASc score. Document the CHA₂DS₂-VASc score for AFib patients. A score ≥2 (men) or ≥3 (women) indicates anticoagulation is recommended — and for high-risk patients, clinical guidelines recommend the superior DOAC option, not the cheapest.

Step-by-Step Appeal

Step 1: Request written denial with full PA criteria. Get the insurer's complete Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization policy document. Identify every criterion that must be met and which one was not satisfied.

Step 2: Have your cardiologist or internist document clinical necessity. The physician letter should include:

• Diagnosis with correct ICD-10 code
• CHA₂DS₂-VASc score (for AFib)
• Specific reason warfarin is clinically inappropriate (labile INR, renal impairment, drug interactions, monitoring barriers, prior adverse events)
• Citation to AHA/ACC/HRS 2023 guideline Class I recommendation for DOACs

Step 3: Invoke state step therapy override law. Most states require a step therapy override when the prior drug has been tried and failed, is contraindicated, or when the clinical guidelines recommend the requested drug. Cite your state's specific statute.

Step 4: Request peer-to-peer review. A cardiologist or hematologist who knows the ARISTOTLE data can make a compelling peer-to-peer case. These calls resolve many Eliquis denials faster than written appeals alone.

Step 5: File for External Independent Review: Complete Guide" class="auto-link">external review if internal appeal fails. External reviewers apply clinical standards independently. The ARISTOTLE data and AHA Class I guideline recommendation are compelling external review arguments.

Non-Preferred Formulary Appeals

If the plan covers another DOAC as preferred:

• Request a formulary exception based on clinical need
• Document why the preferred DOAC is not appropriate: prior intolerance, drug interactions specific to the preferred agent, or patient's renal function favoring apixaban's clearance profile
• Note: apixaban is the only DOAC that demonstrated all-cause mortality reduction in ARISTOTLE

Documentation Checklist

• Denial letter with PA criteria cited
• Physician letter: diagnosis, ICD-10 code, CHA₂DS₂-VASc score (if AFib), warfarin contraindication or failure documentation
• AHA/ACC/HRS 2023 guideline citation (Class I, Level A for DOACs in non-valvular AFib)
• ARISTOTLE trial citation (for AFib) or AMPLIFY trial (for DVT/PE)
• Prior INR monitoring records (if labile INR is the argument)
• Renal function labs (if renal impairment is the argument)
• Medication list documenting drug interactions (if drug interaction is the argument)
• State step therapy override law citation

Cost Assistance While Appealing

• Bristol Myers Squibb/Pfizer Eliquis patient assistance: Free drug for qualifying uninsured/underinsured patients
• Eliquis copay card: Commercially insured patients may pay as little as $10/month
• Generic apixaban: Now available at significant discount through Mark Cuban Cost Plus Drugs and GoodRx

Fight Back With ClaimBack

Eliquis denials require ARISTOTLE trial data, AHA guideline citations, and state step therapy law arguments — all tailored to your specific indication and state. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal